Eupraxia Pharmaceuticals Inc experienced a notable surge in its stock price, closing up over 8% in yesterday's trading session.
Eupraxia Pharmaceuticals Inc (EPRX.TO) saw its stock climb by 8.06% yesterday, closing at CA$10.05. This uptick comes amid a backdrop of positive sentiment surrounding the company, particularly following recent financial disclosures and clinical trial updates.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$612.93M
52W high
$12.86
52W low
$6.94
1W change
+5.79%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 59.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+59.2% Upside
Current Price
C$10.05
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
60.6%
Annualized
90-Day Vol
56.8%
Annualized
Trend (90d)
-6.2%
Annualized drift
90d Mean
C$9.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.98 | C$8.09 – C$12.30 |
| 60 trading days | C$9.90 | C$7.37 – C$13.31 |
| 90 trading days | C$9.83 | C$6.84 – C$14.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should monitor Eupraxia's ongoing clinical trials and financial health, as these factors could significantly influence future stock performance.
Eupraxia Pharmaceuticals Inc Market Cap Reaches CA$664 Million
The company’s market capitalization now stands at approximately CA$664 million, reflecting increased investor interest and confidence.
Bull case
The recent surge suggests that investors are growing more confident in Eupraxia's pipeline. Promising data from its EP-104GI trials and new executive appointments could improve the company’s operational efficiency and attract further investment.
Bear case
Despite the positive movement, it’s wise for investors to stay cautious. The lack of immediate news or catalysts after this surge might lead to fluctuations in the stock price.
Recent Performance Overview
Advertisement
Eupraxia Pharmaceuticals Inc's stock surged by 8.06% in yesterday's session, closing at CA$10.05. This performance reflects a growing optimism among investors, particularly in light of the company's recent financial results and the promising data emerging from its clinical trials.
Market Reaction and Future Outlook
The increase in Eupraxia's stock price signals a positive market reaction to its ongoing developments. Investors are keenly watching the outcomes of the EP-104GI trials, which could be pivotal for the company's future. Additionally, the recent strategic appointments within the company may enhance its operational capabilities, further boosting investor confidence.
Key Financial Metrics
Eupraxia Pharmaceuticals Inc currently holds a market cap of approximately CA$664 million. While the company does not have a P/E ratio or dividend yield to report, the recent stock performance indicates a strong interest in its growth potential, especially as it navigates through critical clinical phases.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
